EP4027983
MEÐFERÐ VIÐ NÝÆÐASJÚKDÓMUM Í AUGUM MEÐ AAV2 AFBRIGÐUM SEM KÓÐA FYRIR AFLIBERCEPT
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
10.9.2020EP published:
19.11.2025EP application number:
20780467.5
EP translation filed:
6.2.2026Grant published:
11.3.2026EPO information:
European Patent Register
Max expiry date:
9.9.2040Expiry date:
9.9.2026
Title in English:
TREATMENT OF OCULAR NEOVASCULAR DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPTLanguage of the patent:
English
Timeline
Today
10.9.2020EP application
19.11.2025EP Publication
6.2.2026Translation submitted
11.3.2026Registration published
9.9.2026Expires
Owner
Name:
Adverum Biotechnologies, Inc.Address:
100 Cardinal Way, Redwood City, CA 94063, US
Inventor
Name:
GASMI, MehdiAddress:
Redwood City, California 94063, US
Name:
KISS, SzilardAddress:
Redwood City, California 94063, US
Name:
OSBORNE, AaronAddress:
Redwood City, California 94063, US
Name:
TURPCU, AdamAddress:
Redwood City, California 94063, US
Agent
Name:
Novagraaf BrevetsAddress:
Bâtiment O2, 2 rue Sarah Bernhardt CS90017, FR
Priority
Number:
201962899070 PDate:
11.9.2019Country:
US
Number:
201962913648 PDate:
10.10.2019Country:
US
Number:
PCT/US2019/062066Date:
18.11.2019Country:
WO
Number:
202062959784 PDate:
10.1.2020Country:
US
Number:
202062971835 PDate:
7.2.2020Country:
US
Number:
202063019190 PDate:
1.5.2020Country:
US
Number:
202063030819 PDate:
27.5.2020Country:
US
Number:
202063063203 PDate:
7.8.2020Country:
US
Classification
Categories:
A61K 31/00, A61K 35/761, A61K 38/17, C12N 7/00, C12N 15/86, A61P 27/02